{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:10:09Z","timestamp":1746159009215,"version":"3.40.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.7759\/cureus.83298","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:25:13Z","timestamp":1746109513000},"source":"Crossref","is-referenced-by-count":0,"title":["Balancing Act: Evaluating the Impact of Direct Oral Anticoagulants on Gastrointestinal Complications in Atrial Fibrillation Patients"],"prefix":"10.7759","author":[{"given":"Rakahn","family":"Haddadin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srusty","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Trad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh SS","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al.. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014, 129:837-47. 10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla S","year":"2013","unstructured":"Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013, 112:1142-7. 10.1016\/j.amjcard.2013.05.063","journal-title":"Am J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go AS","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001, 285:2370-5. 10.1001\/jama.285.18.2370","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf PA","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991, 22:983-8. 10.1161\/01.str.22.8.983","journal-title":"Stroke"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons","volume":"140","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al.. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019, 140:e125-51. 10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof P","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al.. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016, 37:2893-962. 10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:373-498. 10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","author":"Abraham NS","year":"2015","unstructured":"Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015, 350:h1857. 10.1136\/bmj.h1857","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip GY","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016, 116:975-86. 10.1160\/TH16-05-0403","journal-title":"Thromb Haemost"},{"key":"ref13","unstructured":"Drug approval package. (2010). Accessed. 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512orig1s000toc.cfm."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy JH","year":"2016","unstructured":"Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016, 14:623-7. 10.1111\/jth.13227","journal-title":"J Thromb Haemost"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster IL","year":"2013","unstructured":"Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013, 145:105-12.e15. 10.1053\/j.gastro.2013.02.041","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf J","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S, et al.. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014, 124:955-62. 10.1182\/blood-2014-03-563577","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.480","article-title":"Management of patients with ulcer bleeding","volume":"107","author":"Laine L","year":"2012","unstructured":"Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012, 107:345-60; quiz 361. 10.1038\/ajg.2011.480","journal-title":"Am J Gastroenterol"},{"key":"ref18","article-title":"Physicians' perceptions of anticoagulant therapy and the risk of bleeding","volume":"135","author":"Kovacs MJ","year":"2015","unstructured":"Kovacs MJ, Hurst E, Kearon C, Carroll C, Sudicky M, Crowther M, Bates SM. Physicians' perceptions of anticoagulant therapy and the risk of bleeding. Thromb Res. 2015, 135:1199-203.","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014, 383:955-62. 10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in\u00a0patients with advanced chronic kidney\u00a0disease or on dialysis with AF","volume":"67","author":"Chan KE","year":"2016","unstructured":"Chan KE, Giugliano RP, Patel MR, et al.. Nonvitamin K anticoagulant agents in\u00a0patients with advanced chronic kidney\u00a0disease or on dialysis with AF. J Am Coll Cardiol. 2016, 67:2888-99. 10.1016\/j.jacc.2016.02.082","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0317-5","article-title":"Hepatotoxicity of new oral anticoagulants (NOACs)","volume":"38","author":"Liakoni E","year":"2015","unstructured":"Liakoni E, R\u00e4tz Bravo AE, Kr\u00e4henb\u00fchl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015, 38:711-20. 10.1007\/s40264-015-0317-5","journal-title":"Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala MS","year":"2012","unstructured":"Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012, 40:2250-5. 10.1124\/dmd.112.046888","journal-title":"Drug Metab Dispos"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-023-00582-9","article-title":"Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion","volume":"23","author":"Martin AC","year":"2023","unstructured":"Martin AC, Benamouzig R, Gouin-Thibault I, Schmidt J. Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion. Am J Cardiovasc Drugs. 2023, 23:407-18. 10.1007\/s40256-023-00582-9","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier J","year":"2009","unstructured":"Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009, 15:9S-16S. 10.1177\/1076029609343004","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack CV Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, et al.. Idarucizumab for dabigatran reversal. N Engl J Med. 2015, 373:511-20. 10.1056\/NEJMoa1502000","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353359-balancing-act-evaluating-the-impact-of-direct-oral-anticoagulants-on-gastrointestinal-complications-in-atrial-fibrillation-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:25:15Z","timestamp":1746109515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353359-balancing-act-evaluating-the-impact-of-direct-oral-anticoagulants-on-gastrointestinal-complications-in-atrial-fibrillation-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.83298","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}